Xcell Therapeutics

At a glance

Xcell Therapeutics filed 47 disclosures in the last 12 months, including 12 insider, 4 5% holder, 1 earnings and 1 m&a. The most recent key filing was on Oct 27: A major holder's stake fell from 18.75% to 18.65% (open-market buy).

Revenue for 2025 was ₩1.9B, up 0.8% on 2024. It made an operating loss of ₩10.9B. Debt was 120% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩3B and operating loss of ₩5.7B.

The 2025 annual report lists 65 employees with an average tenure of 3 years and average pay of ₩66.7M, #700 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩83M each on average. It paid no cash dividend for 2025. 이의일 and related parties held 11.76% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 18.65% on Oct 27.

From the 2025 annual report

Staff: 65 (33 men, 32 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩4.3B. Directors and auditors: 7, paid ₩581M in total.

No cash dividend was paid for 2025.

Largest shareholder

이의일 holds 11.68%; with 1 related party the group holds 11.76% of common shares at year end (from 15.75% at the start of the year).

Auditor: 삼화회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports